Dolphin Care ApS — Regnskab

CVR 37517690

Seneste regnskabsperiode

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 799000 • -1578521 • -6549522 • 10603156 • -4577235 • 1

Regnskabshistorik

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -1919312 • -5215319 • -4570551 • 10915202 • 1972292 • 3
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -4225769 • -7350622 • -6111943 • 10372664 • 4542843 • 3
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • -226938 • -2414398 • -2149665 • 12828746 • 7154786 • 1
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • -3043625 • -4832397 • 13611859 • 9304451 • 2
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 294000 • -120326 • -218676 • 15413571 • 14136848 • 1
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • -403943 • -523100 • 7069980 • 3854416 • 1
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • -2414572 • -2168564 • 6472534 • -3007905 • 1
  • 2017 • 2017-01-01 • 2017-12-31 • entity • DKK • -336000 • -417000 • 6051000 • -839000 • 1

Højdepunkter fra årsrapporten

  • primary activities • Business reviewDolphin Care develops and manufactures innovative UV-C based technologies for infection prevention in healthcare environments. The company’s products are designed to reduce the transmission of bacteria, viruses and fungi on surfaces, in air and in water systems. The company’s vision is to become one of the world’s leading developers of life-saving infection prevention technology. The company continues to expand its international activities through distributors, strategic partnerships and regulatory initiatives in key healthcare markets. • entity
  • development in activities and financial affairs • Financial review The company's income statement for the year ended 31 December 2025 shows a loss of DKK 6.549.522, and the balance sheet at 31 December 2025 shows negative equity of DKK 4.577.235.During 2025, the company continued its international commercial activities and further developed its distribution network in key healthcare markets. Revenue increased significantly compared to the previous year; however, the company continued to invest significantly in product development, regulatory activities, market expansion and protection of intellectual property rights. The company remains focused on long-term value creation through international growth and continued development of its infection prevention technologies.FinancingDuring the year, the company secured additional funding from existing investors and lenders to support its continued development and international expansion. Management expects that the company will continue to have access to the funding required to support its planned activities. • entity
  • result compared with expectations • Profit/(loss) for the year relative to the expectations most recently expressedThe result for the year was below management’s original expectations. The deviation was primarily attributable to delays in the commercialisation of planned activities and continued investments in product development, regulatory activities, international market development and protection of intellectual property rights. • entity
  • recognition measurement uncertainty • The carrying amount of all intangible assets in amortized over their expected usefull lives. Each year, management assesses whether there are indications of possible impairment, based on both budgets and sensitivity analyses, to ensure that the expected value of futue cash flows exceeds the carrying amount of capitalized development costs. The budgets underlying this assessment are based on assumptions of significant futues growth in the company's acivities, and although a realistiv evaluation is sought, these estimates are subject to uncertainty. The actual outcome may turn out to be either better of worse than expedsted in terms of both amount and timing. Accordingly, the carrying amount of intangible assets in based on mangement's estimates and assumptions and is therefore subject to uncertainty. Reference is made to note 4 regarding intangible assets. • entity
  • subsequent events • Significant events occurring after the end of the financial yearFollowing the end of the financial year, the company has continued to expand its international commercial activities and distributor network. Work related to regulatory approvals, including activities associated with the company’s planned FDA submission and market access in selected international markets is progressing according to plan. No events have occurred after the balance sheet date that materially affected the company’s financial position. • entity
  • contingent liabilities • The company has a 6-month rent obligation of DKK 172.422. • entity
  • mortgages collateral • The Company has no pledged assets or other collateral. • entity